BioSpace News Archive

RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Guy Goldberg, RedHill’s Chief Business Officer, will present a corporate overview and host 1-on-1 investor meetings at the German Equity Forum (Deutsches Eigenkapital Forum) 2020, one of Europe’s largest investor events, on Tuesday, November 17, 2020, at 9:30 a.m. CET . The presentation

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA; TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended September 30, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted. “Over the last several months, we have achieved key clinical, regulatory, and corporate milestones that have left us well posit

NANOSCOPE THERAPEUTICS Inc., a clinical-stage biotechnology company determined to change lives through the ocular gene therapy based on its proprietary ambient light activatable MCO Optogenetic Technology Platform, today announced that an oral presentation at the Late Breaking Developments session of Retina Subspecialty Day will

Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2020. Fourth Quarter 2020 Highlights (Comparison to Fourth Quarter Fiscal 2019): Consolidated Net Revenue of $64.2 million, up 26% year-over-year Life Science segment delivers revenue of $34.4 million, up 97% year-over-year Diagnostics segment revenues decreased 11% year-over-year to $29.8 million, a stronger

Poster presentations highlight AXA1125’s multifactorial activity; potentially differentiating and enhanced effects in subjects with type 2 diabetes

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ: INM) (TSX: IN), today reported financial results for the first quarter of fiscal year 2021 (“1Q21") which ended September 30, 2020.

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will participate in 1x1 investor meetings at the virtual Guggenheim Securities Healthcare Talks. Additionally, Dr. Ben-Maimon will present a fireside chat and participate in 1x1 investor meetings at the Piper

Addition al data from SIGNAL Huntington’s disease (HD) trial support continued development in H D and in Alzheimer’s disease (AD) Phase 1/2 Study to Evaluate Pepinemab in Combination with KEYTRUDA ® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for H1 2021 Ended the quarter with cash and cash equivalents of $17.1 million

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020 at 4:00 p

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) (“China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its third quarter 2020 financial results on Tuesday, November 24, 2020 after the market closes.